<DOC>
	<DOCNO>NCT00004647</DOCNO>
	<brief_summary>OBJECTIVES : I. Assess efficacy toxicity mexiletine management paresthesia pain patient diabetic neuropathy .</brief_summary>
	<brief_title>Phase III Randomized , Double-Blind , Placebo-Controlled Study Mexiletine Painful Diabetic Neuropathy</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double-blind study . Patients stratify participate institution . The first group receive oral mexiletine 3 time day 6 week . The dose increase first week side effect . The second group receive placebo . Patients cross alternate treatment 1-week washout .</detailed_description>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Paresthesia</mesh_term>
	<mesh_term>Mexiletine</mesh_term>
	<criteria>Patients painful diabetic neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 1999</verification_date>
	<keyword>diabetic neuropathy</keyword>
	<keyword>disease-related problem/condition</keyword>
	<keyword>neurologic psychiatric disorder</keyword>
	<keyword>pain</keyword>
	<keyword>rare disease</keyword>
</DOC>